Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Shares Outstanding for 6 consecutive years, with $63443.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding changed 0.0% year-over-year to $63443.0, compared with a TTM value of $63443.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $63443.0, changed 0.0% over the prior year.
  • Shares Outstanding was $63443.0 for Q3 2025 at Barinthus Biotherapeutics, roughly flat from $63443.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $40.2 million in Q4 2024 and bottomed at $63443.0 in Q2 2022.
  • Average Shares Outstanding over 5 years is $11.8 million, with a median of $317215.0 recorded in 2021.
  • The sharpest move saw Shares Outstanding surged 58679.52% in 2022, then plummeted 99.84% in 2025.
  • Year by year, Shares Outstanding stood at $37.2 million in 2021, then plummeted by 98.46% to $570987.0 in 2022, then plummeted by 88.89% to $63443.0 in 2023, then changed by 0.0% to $63443.0 in 2024, then changed by 0.0% to $63443.0 in 2025.
  • Business Quant data shows Shares Outstanding for BRNS at $63443.0 in Q3 2025, $63443.0 in Q2 2025, and $63443.0 in Q1 2025.